DF/HCC 肾癌孢子-猫眼课题宝

DF/HCC 肾癌孢子

批准号：

7644693

负责人：

Michael Benjamin Atkins

金额：

$116.53万

依托单位：

BETH ISRAEL DEACONESS MEDICAL CENTER

依托单位国家：

美国

项目类别：

财政年份：

2003

资助国家：

美国

项目状态：

已结题

起止时间：

2003-09-18 至 2009-05-31

来源：

https://reporter.nih.gov/project-details/7644693

关键词：

Address Affect Allogenic Angiogenesis Inhibitors Animal Model Antigens Apoptosis Area Arts Autologous Dendritic Cells Autologous Tumor Cell Award Bilateral Binding Bioinformatics Biological Biological Assay Biological Markers Biology Biometry Bladder Blood Vessels Blood flow CCI-779 Cancer Center Cancer Vaccines Carcinoma in Situ Caring Cell Line Cell Proliferation Cell fusion Cells Clear Cell Clinic Clinical Clinical Data Clinical Pathology Clinical Research Clinical Trials Coagulation Process Collaborations Communities Complement Contralateral Conventional (Clear Cell) Renal Cell Carcinoma Correlation Studies Cytolysis Dana-Farber Cancer Institute Data Data Correlations Data Set Dendritic Cells Development Disease Disease Progression Disease regression Dose Early Diagnosis Effectiveness Endothelial Cells Epidermal Growth Factor Receptor European Evaluation Excision Exhibits Family Funding Future Gene Expression General Hospitals Generations Genes Genetic Goals Grant Growth Factor Growth Factor Receptors Head Hospitals Hypoxia Inducible Factor Image Immune Immune Targeting Immunity Immunologic Monitoring Immunologics Immunotherapy In Situ Hybridization In Vitro Institutes Interferons Interleukin-12 Interleukin-2 Invasive Investigation Israel K-Series Research Career Programs Kidney Knowledge Laboratories Lead Local Therapy Localized Disease Lung Magnetic Resonance Imaging Malignant neoplasm of kidney Massachusetts Mediating Medical Oncologist Medical center Methods Microscopic Modality Modeling Molecular Monitor Mutation Nature Neoplasm Metastasis Nephrectomy Other Therapy Outcome PTK787 PTK787/ZK 222584 Pathologic Pathology Pathway interactions Patients Pediatric Hospitals Performance Perfusion Pharmaceutical Preparations Pharmacologic Substance Phase Phase I Clinical Trials Phase II Clinical Trials Phase III Clinical Trials Plasma Platelet-Derived Growth Factor Platelet-Derived Growth Factor Receptor Play Population Predisposition Principal Investigator Productivity Proteomics Public Health Schools Radiofrequency Interstitial Ablation Reaction Time Receptor Protein-Tyrosine Kinases Recording of previous events Recurrence Recurrent disease Refractory Relapse Renal Cell Carcinoma Renal carcinoma Reporting Reproduction spores Research Research Personnel Research Priority Resistance Resources Rewards Risk Role Sampling Science Screening procedure Series Serum Serum Markers Signal Pathway Signal Transduction Skates Skating Solid Neoplasm Specialized Program of Research Excellence Specific qualifier value Specimen Staging Standards of Weights and Measures Surface T-Cell Proliferation T-Lymphocyte TNF gene Techniques Testing Therapeutic Thinking Time TimeLine Tissues Toxic effect Transgenic Organisms Translational Research Translations Treatment outcome Tumor Antigens Tumor Debulking Tumor Suppressor Genes Tumor Tissue United States Food and Drug Administration United States National Institutes of Health Urine Urologist Vaccination Vaccines Validation Vascular Endothelial Growth Factors Von Hippel-Lindau Syndrome Woman Work Xenograft procedure anergy angiogenesis authority autocrine base cancer therapy carcinogenesis clinical efficacy cohort cost design gain of function heterokaryon human study immune function improved in vitro Assay in vivo inhibitor/antagonist insight interest kidney cell loss of function member mouse model neoplastic cell novel novel strategies outcome forecast paracrine preclinical study prognostic programs protein expression radiofrequency receptor research study response restoration size small molecule software development tool translational clinical trial translational study treatment program tumor tumorigenesis

项目摘要

项目成果

Michael Benjamin Atkins的其他基金

相似基金

相关文献

中文摘要

翻译

描述（由申请人提供）：本申请代表了新成立的丹娜-法伯哈佛癌症中心（DF/HCC）和贝斯以色列女执事医疗中心的肾癌项目发展中肾癌研究卓越专业项目的创建。DF/HCC肾癌孢子包括来自所有哈佛附属医院的研究人员-贝斯以色列女执事医疗中心，丹娜-法伯癌症研究所，马萨诸塞州总医院，布里格姆妇女医院，儿童医院医疗中心，以及哈佛公共卫生学院。通过该应用程序支持五个主要项目，包括：1)识别早期发现和监测高危RCC人群的标记；2)抑制vhl调控的生长因子通路治疗RCC；3)射频消融联合抗血管/抗血管生成治疗RCC；4)确定RCC预后和治疗反应性的分子和免疫学相关因素；5)树突状细胞/肿瘤融合与IL-12联合作为RCC的新型免疫疗法。这些项目由四个核心集成。它们是：1)行政、评价和规划；2)生物统计学;3)组织采集，病理和临床数据，4)监测。这个《孢子》应用程序概述了一个发展项目计划，其中包括一个项目选择和审查计划，以及八个可以考虑支持的样本项目。我们还包括一个职业发展奖励计划，该计划概述了识别、支持和审查肾癌领域有才华的年轻研究者的机制。DF/HCC肾癌孢子的总体目标是将生物学和技术进步转化为对肾癌患者有临床意义的进展。

英文摘要

DESCRIPTION (provided by applicant): This application represents the creation of a Specialized Program of Research Excellence in Renal Cancer originating from the Renal Cancer Program-in-Development of the newly configured Dana-Farber Harvard Cancer Center (DF/HCC) and the Beth Israel Deaconess Medical Center. The DF/HCC Renal Cancer SPORE includes investigators from all the Harvard affiliated hospitals - the Beth Israel Deaconess Medical Center, the Dana-Farber Cancer Institute, the Massachusetts General Hospital, the Brigham and Women's Hospital, and the Children's Hospital Medical Center, as well as the Harvard School of Public Health. Five major projects are supported through this application including: 1) Identification of markers for early detection and monitoring of high-risk RCC populations; 2) Inhibition of VHL-regulated growth factor pathways for treatment of RCC; 3) Combination radiofrequency ablation and antivascular/anitangiogenesis therapy for RCC; 4) Identification of molecular and immunologic correlates of RCC prognosis and responsiveness to therapy, and 5) Dendritic cell/tumor fusions in conjunction with IL-12 as novel immunotherapy for RCC. These projects are integrated by four cores. These are: 1) Administration, Evaluation and Planning; 2) Biostatistics; 3) Tissue Acquisition, Pathology and Clinical Data, and 4) Monitoring. This SPORE application outlines a Developmental Projects Program which includes a plan for selection and review of projects, and eight sample projects that could be considered for support. We also include a Career Development Award Program which outlines a mechanism for the identification, support, and review of talented young investigators in renal cancer. The overall goal of the DF/HCC Renal Cancer SPORE is the translation of biological and technological advances into clinically meaningful advances for patients with renal cancer.

期刊论文(0)

专著(0)

科研奖励(0)

会议论文